GHRH Analog Pharmacology Overview
Growth hormone releasing hormone (GHRH) is a 44-amino acid hypothalamic peptide that stimulates somatotroph cells in the anterior pituitary to produce and secrete growth hormone. Synthetic GHRH analogues are engineered variations that improve upon endogenous GHRH's short half-life (~7 minutes in plasma) through DPP-IV resistance, albumin binding, or structural stabilization. The three primary research-grade GHRH analogues differ significantly in their pharmacokinetic profiles and the research questions each is best suited to address.
CJC-1295 DAC incorporates a Drug Affinity Complex at a substituted lysine residue that forms a covalent bond with circulating albumin's Cys-34 thiol group. This albumin conjugation dramatically extends the functional half-life to approximately 6-8 days by protecting the peptide from proteolytic degradation and renal clearance. The result is a sustained, non-pulsatile pattern of GHRH-R stimulation — a fundamentally different GH secretion profile compared to shorter-acting analogues. Research applications include long-duration GHRH-R agonism studies, comparison of sustained vs. pulsatile GH release, and albumin-binding pharmacokinetic research.
Tesamorelin is a full-length GHRH(1-44) analogue stabilized by conjugation of trans-3-hexenoic acid to the N-terminal tyrosine residue. This modification improves DPP-IV resistance while preserving the complete 44-amino acid sequence of native GHRH — an important distinction from truncated analogues like Sermorelin (29 aa) and CJC-1295 (29 aa). For research requiring the highest receptor sequence fidelity, Tesamorelin provides a pharmacologically stable full-length reference compound with an intermediate half-life of approximately 30 minutes.
Sermorelin is the N-terminal 29-amino acid amidated fragment of GHRH — the minimal sequence required for full GHRH-R binding and activation. Its short half-life of 11-20 minutes produces a pulsatile GH release pattern and allows precise, time-controlled receptor stimulation in research designs requiring well-defined activation windows. As the original synthetic GHRH research tool (developed in the 1980s), Sermorelin has the longest publication history and is used as the reference compound when comparing truncated vs. full-length vs. DAC-modified GHRH analogues.
GHRH Analog Comparison
| Parameter | Sermorelin | CJC-1295 No DAC | Tesamorelin | CJC-1295 DAC |
|---|---|---|---|---|
| Sequence | GHRH(1-29) | GHRH(1-29) mod | GHRH(1-44) | GHRH(1-29) mod |
| Half-life | ~15 min | ~30 min | ~30 min | ~7 days |
| GH Pattern | Pulsatile | Pulsatile | Pulsatile | Sustained |
| Sequence Fidelity | Truncated | Truncated mod | Full-length | Truncated mod |
| DPP-IV Resistance | Low | High | Moderate | Very high |
Research Design Selection Guide
Use Sermorelin for historical comparison studies, minimal GHRH fragment pharmacology research, or short pulse designs requiring precise activation timing with rapid clearance.
Use CJC-1295 No DAC for pulsatile GH release models with improved DPP-IV resistance, or as the pulsatile comparator against DAC-modified protocols.
Use Tesamorelin when full-length GHRH sequence fidelity is required — receptor binding studies where the C-terminal extension of native GHRH may be mechanistically relevant.
Use CJC-1295 DAC for sustained GHRH-R agonism, long-duration GH secretion studies, or albumin-binding pharmacokinetic research requiring a defined covalent binding mechanism.